DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Woyach JA, Ruppert AS, Heerema NA. et al.
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202.
Blood 2018;
132: 6
We do not assume any responsibility for the contents of the web pages of other providers.